From the *Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany; and †Private Office for Urology, Bonn, Germany.
Clin Nucl Med. 2016 Jul;41(7):572-3. doi: 10.1097/RLU.0000000000001200.
An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.
一位 80 岁的去势抵抗性前列腺癌患者因前列腺特异性抗原（PSA）水平升高到我科进行 PSMA 成像。该肿瘤于 2004 年诊断。患者仅接受了促性腺激素释放激素类似物治疗。两次 Lu-PSMA-617 治疗，两次治疗之间间隔 2 个月。完成 2 个周期的 Lu-PSMA 治疗后 10 个月，我们注意到在激素治疗下的 PET/CT 成像中 PSA 水平持续下降，肿瘤扩散减少。
